Postmenopausal Hormone Therapy: Balancing Endometrial Protection and Cancer Risk
Updated evidence shows unopposed estrogen increases endometrial hyperplasia risk, while combined regimens offer better protection.
Trastuzumab Deruxtecan plus Pertuzumab Becomes First-Line Standard for HER2‑Positive Metastatic Breast Cancer: Clinical Implications of the DESTINY‑Breast09 Approval
The FDA has approved trastuzumab deruxtecan with pertuzumab as first-line therapy for unresectable or metastatic HER2‑positive breast cancer after DESTINY‑Breast09 showed a large PFS benefit versus standard THP; safety and maintenance strategy questions remain.
Posted innews Oncology Psychiatry
CBT‑I in Cancer Survivors: Small Subjective Gains, Unclear Objective Benefits — What the 2025 Cochrane Review Tells Clinicians
A 2025 Cochrane review of 21 RCTs (2431 participants) finds cognitive behavioural therapy for insomnia (CBT‑I) yields modest improvements in self‑reported insomnia and sleep quality in people with cancer versus inactive controls or aerobic activity; objective sleep changes and long‑term effects remain uncertain.
Posted inGastroenterology news Oncology
Intraperitoneal Chemotherapy for Gastric Cancer: Promising Survival Signals but Very Low‑Certainty Evidence
A Cochrane review of nine RCTs (829 patients) found low‑certainty signals that intraperitoneal chemotherapy (mainly HIPEC) may improve overall survival in high‑risk and metastatic gastric cancer, but evidence is very uncertain due to bias, imprecision, and limited safety and QOL data.
Acupuncture for Cancer-Related Insomnia: Limited, Low-Certainty Benefits Compared with Sham or No Treatment; Inferior to CBT‑I
A 2025 Cochrane review (5 RCTs, 402 patients, mainly women with breast cancer) finds very low- to moderate-certainty evidence that acupuncture delivers small, uncertain sleep diary benefits versus sham or inactive controls and is probably less effective than CBT‑I for insomnia in people with cancer.
FDA Greenlights Niraparib–Abiraterone–Prednisone for BRCA2‑Mutated Metastatic Castration‑Sensitive Prostate Cancer: Implications and Practical Considerations
The FDA approved once‑daily niraparib plus abiraterone acetate and prednisone for adults with deleterious or suspected deleterious BRCA2‑mutated metastatic castration‑sensitive prostate cancer (CSPC), based on rPFS and interim overall survival benefits in the AMPLITUDE trial.
Breast Cancer Index in Premenopausal HR+ Disease: Prognostic Confirmed, Predictive Role for OFS-Intensification Context-Dependent
Two large prospective‑retrospective analyses confirm BCI as a robust prognostic biomarker in premenopausal HR+ breast cancer; its HOXB13/IL17BR (H/I) component predicted benefit from adding ovarian function suppression versus tamoxifen alone but did not clearly predict superiority of exemestane+OFS over tamoxifen+OFS.
Early‑Onset Colorectal Cancer: Parsing an Epidemiologic Artifact from True Molecular Signals — Toward a Clinically Actionable Molecular Taxonomy
Integrated analysis shows a 2013 NEN classification change inflated EOCRC counts in the youngest adults, while independent molecular studies reveal distinct hypermutated and non‑hypermutated EOCRC subtypes with higher MSI/TMB and pathway-specific differences across populations. Implications for diagnosis, surveillance, and precision therapy are discussed.
Posted inClinical Updates Gastroenterology news Oncology
Proton Pump Inhibitor Use and Survival Outcomes in Newly Diagnosed Glioblastoma: An Evidence-Based Review
Proton pump inhibitor use, particularly potent ALDH1A1-activating PPIs, is associated with worse survival in newly diagnosed glioblastoma, highlighting the need for cautious use and further mechanistic research.
Atezolizumab–Bevacizumab Provides the Best Balance of Survival and Quality of Life in First‑Line Advanced Hepatocellular Carcinoma
A Bayesian network meta-analysis integrating health‑related quality of life and overall survival across first‑line trials in advanced hepatocellular carcinoma shows atezolizumab plus bevacizumab provides the most favorable combined patient‑centered outcome profile.
Neoadjuvant Checkpoint Inhibitors with Chemotherapy Improve Outcomes in Early Triple‑Negative and PD‑L1+ HR‑Positive Breast Cancer — A Critical Appraisal of Recent Meta‑Analysis
A patient‑level and trial‑level meta‑analysis of nine RCTs (5,114 patients) shows that adding immune checkpoint inhibitors to neoadjuvant chemotherapy improves pathologic complete response and event‑free survival in triple‑negative breast cancer and PD‑L1+ HR+/ERBB2‑ tumors, with a manageable immune toxicity profile.
Posted innews Oncology Psychiatry
Late-Onset Depression Risk Persists in Long-Term Breast, Prostate, and Colorectal Cancer Survivors — Who Is Most Vulnerable?
A SEER‑Medicare cohort study found higher 5‑year risk of late-onset depression in breast (13.3%) and colorectal (11.8%) survivors than prostate (8.7%). Dual Medicare‑Medicaid eligibility, preexisting anxiety, and higher comorbidity burden were consistent, independent risk factors.
Posted inHematology-Oncology news Oncology
Rising Immunotherapy Use at Cancer End of Life Is Linked to More Hospital-Based Care: What Clinicians Need to Know
In a population-based Ontario study, use of systemic anticancer therapy (SACT) in the last 30 days of life increased—driven by immunotherapy—and was associated with higher emergency visits, hospitalizations, ICU admissions, and hospital death across all SACT types.
Posted inClinical Updates news Oncology
Risk and Outcomes of Secondary Cancer Among Lung Cancer Survivors After Definitive Treatment: A Comprehensive Review
This review synthesizes evidence on the incidence, risk factors, and outcomes of secondary cancers in non-small cell lung cancer survivors post-definitive therapy, highlighting genetic predisposition as a key determinant distinct from recurrence patterns.
Posted inHematology-Oncology news Oncology
Rising Use of Novel Systemic Anticancer Therapies at End of Life Is Associated With More Hospital-Based Care
Use of systemic anticancer therapy in the last 30 days of life rose from 2015–2020, mainly due to immunotherapy; any SACT was linked to more than twofold higher odds of multiple ED visits, hospitalizations, ICU admission, and in-hospital death. Guidelines should address novel agents.
Posted inHematology-Oncology news Oncology
Systemic Anticancer Therapy in the Last 30 Days of Life Is Tied to More Acute Care and Less Hospice Use in Older Adults: A SEER–Medicare Analysis
A SEER–Medicare study of 315,089 older adults found that systemic anticancer therapy within 30 days of death—whether cytotoxic, targeted, immunotherapy, or combinations—was associated with substantially higher acute care use and lower hospice enrollment.
Proton Craniospinal Irradiation Improves CNS Progression-Free and Overall Survival in Leptomeningeal Metastasis: Randomized Phase 2 Evidence
In a randomized phase 2 trial, proton craniospinal irradiation (pCSI) significantly improved central nervous system progression‑free survival and overall survival versus involved‑field photon radiotherapy in patients with leptomeningeal metastasis from solid tumors.
Posted inHematology-Oncology news Oncology
Five-Year POLARIX Follow-Up: Polatuzumab-R-CHP Improves Long-Term PFS in Frontline DLBCL — What Clinicians Need to Know
At five years, pola‑R‑CHP showed a sustained progression‑free survival benefit versus R‑CHOP in newly diagnosed intermediate‑/high‑risk DLBCL (HR 0.77), with similar long‑term tolerability and no statistically significant overall survival difference.
Posted innews Oncology Pediatrics
Dose-Dependent Radiation and Chemotherapy Risks for Colorectal Subsequent Malignancies in Childhood Cancer Survivors: Clinical Implications from a CCSS Analysis
A CCSS analysis of 25,723 five-year childhood cancer survivors shows clear dose-response relationships between colorectum-specific radiation dose, irradiated colorectal volume, several chemotherapy exposures (notably procarbazine, high alkylator and platinum doses), and subsequent colorectal cancers, with actionable implications for RT planning and survivorship surveillance.
Posted inHematology-Oncology news Oncology
Mosunetuzumab + Polatuzumab Vedotin Outperforms R‑GemOx in Transplant‑Ineligible Relapsed/Refractory Large B‑Cell Lymphoma: Primary Results of the Phase III SUNMO Trial
In the randomized phase III SUNMO trial, mosunetuzumab plus polatuzumab vedotin significantly improved response rates and progression‑free survival versus R‑GemOx in transplant‑ineligible relapsed/refractory large B‑cell lymphoma, with low rates of clinically significant cytokine release syndrome and improved patient‑reported outcomes.